|View printer-friendly version|
Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
The first poster, entitled Pharmacodynamic studies of SB 11285, a systemically bioavailable STING agonist in orthotopic tumor models, will describe the anti-tumoral activity of SB 11285 in multiple orthotopic and subcutaneous models.
The second poster presentation, entitled SB 11312, an active metabolite of SB 11285, is a potent and systemically bioavailable STING agonist, will highlight anti-tumor activity and safety of SB 11312 administered by multiple routes in syngeneic mouse models.
The third poster, entitled Mechanistic insights into the anti-tumor activity of SB 11285 – a novel STING agonist, provides insights into the mechanism of action of SB 11285 and its analogs.
“We are excited to present data from our next-generation STING agonist program at this important conference on Tumor Immunology and Immunotherapy, particularly in light of the recent presentation at the
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether the results of such trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.